Research comparison
A side-by-side comparison of Semaglutide and Liraglutide as they are characterised in the peer-reviewed research literature. GLP-1 receptor agonist research. Both compounds are supplied for in-vitro laboratory research only.
| Semaglutide | Liraglutide | |
|---|---|---|
| Research area | Metabolic Research | Metabolic Research |
| Sizes stocked | 2mg, 5mg, 10mg, 15mg, 20mg, 30mg | 5mg, 10mg, 30mg |
| Reference | Full Semaglutide page → | Full Liraglutide page → |
Semaglutide is a 31-amino-acid peptide characterised in the literature as an agonist at the glucagon-like peptide-1 (GLP-1) receptor, sharing approximately 94% sequence homology with native human GLP-1. Supplied as lyophilised powder for in-vitro research use only.
Liraglutide is a synthetic GLP-1 receptor agonist with approximately 97% sequence homology to native human GLP-1. Characterised in the research literature as a lipopeptide modification of the parent sequence. Supplied as lyophilised powder for in-vitro research use only.
Both compounds are characterised in the research literature within glp-1 receptor agonist research. Researchers typically consult the primary peer-reviewed publications for each compound before selecting one for a specific experimental protocol. The two are frequently studied in parallel and occasionally cited together in comparative pharmacology reviews.
Both Semaglutide and Liraglutide are supplied as lyophilised powder and reconstituted with bacteriostatic water using standard laboratory technique. For full reconstitution methodology see our Research Handling Guide, or compute resulting mg/ml concentrations with the Reconstitution Volume Calculator.
Every batch of both compounds is independently HPLC-verified by Janoshik Analytical at 99%+ purity. The lab report is supplied with every order and carries a unique verification key.